Document:

EX-4.5

 Exhibit 4.5 

In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which
the omitted executed warrants differ from the form of warrant that follows: 
  

			
	 	 	Number of Shares
		 	157,526
		 	105,017

 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF
LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 

WARRANT TO PURCHASE STOCK 
  

			
	Company:	  	ACUTUS MEDICAL, INC., a Delaware corporation
		
	Number of Shares:	  	[105,017 / 157,526] (Subject to Section 1.7)
		
	Type/Series of Stock:	  	Series C Preferred (Subject to Section 1.7)
		
	Warrant Price:	  	$1.714 per share (Subject to Section 1.7)
		
	Issue Date:	  	July 31, 2018
		
	Expiration Date:	  	July 31, 2028 See also Section 5.1(b).
		
	Credit Facility:	  	This Warrant to Purchase Stock (“Warrant”) is issued in connection with that certain Loan and Security Agreement of even date herewith among Oxford Finance LLC, as Lender and Collateral Agent, the Lenders from time
to time party thereto, and the Company (as modified, amended and/or restated from time to time, the “Loan Agreement”).

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, OXFORD FINANCE LLC
(“Oxford” and, together with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully paid and non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock (the “Class”) of the above-named company (the “Company”) at the above-stated Warrant
Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. 

SECTION 1.    EXERCISE. 

1.1    Method of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part,
by delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix I and, unless Holder is exercising this Warrant pursuant to a cashless exercise set
forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares
being purchased. 
 1.2    Cashless Exercise. On any exercise of this Warrant, in lieu of payment of the
aggregate Warrant Price in the manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which
this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula: 

					
		  	X = Y(A-B)/A
			
	 where:
	  		  	
			
		  	X =	  	the number of Shares to be issued to the Holder;
			
		  	Y =	  	the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);
			
		  	A =	  	the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and
			
		  	B =	  	the Warrant Price.

 1.3    Fair Market Value. If the Company’s common stock is then traded or
quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading Market”) and the
Class is common stock, the fair market value of a Share shall be the closing price or last sale price of a share of common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its
Notice of Exercise to the Company. If the Company’s common stock is then traded in a Trading Market and the Class is a series of the Company’s convertible preferred stock, the fair market value of a Share shall be the closing price or
last sale price of a share of the Company’s common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company multiplied by the number of shares of
the Company’s common stock into which a Share is then convertible. If the Company’s common stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable
good faith judgment. 
 1.4    Delivery of Certificate and New Warrant. Within a reasonable time after Holder
exercises this Warrant in the manner set forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has
not expired, a new warrant of like tenor representing the Shares not so acquired. 
 1.5    Replacement of
Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in
form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant
of like tenor and amount. 
 1.6    Treatment of Warrant Upon Acquisition of Company. 

(a)    Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series
of related transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with another person or entity
(other than a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger,
consolidation or reorganization, own les s than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization (or, if such Company stockholders
beneficially own a majority of the outstanding voting power of the surviving or successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or (iii) any sale or
other transfer by the stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power. 

(b)    Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be
received by the Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), either (i) Holder shall exercise

  
 2 

 
this Warrant pursuant to Section 1.1 and/or 1.2 and such exercise will be deemed effective immediately prior to and contingent upon the consummation of such Acquisition or (ii) if
Holder elects not to exercise the Warrant, this Warrant will expire immediately prior to the consummation of such Acquisition. 

(c)    The Company shall provide Holder with written notice of its request relating to the Cash/Public Acquisition
(together with such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Cash/Public Acquisition giving rise to such notice), which is to be delivered to Holder not less
than seven (7) Business Days prior to the closing of the proposed Cash/Public Acquisition. In the event the Company does not provide such notice, then if, immediately prior to the Cash/Public Acquisition, the fair market value of one Share (or
other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be
exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall promptly notify the Holder of the number of Shares (or such other securities)
issued upon such exercise to the Holder and Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as the date thereof. 

(d)    Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or
successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of
this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this Warrant. 

(e)    As used in this Warrant, “Marketable Securities” means securities meeting all of the following
requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its
filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to
exercise this Warrant on or prior to the closing thereof is then traded in Trading Market, and (iii) following the closing of such Acquisition, Holder would not be restricted from publicly re-selling all
of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise or convert this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such
restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Acquisition. 

1.7    Adjustment to Class of Shares; Number of Shares; Warrant Price; Adjustments Cumulative.
Upon the closing of the Next Equity Financing, the “Class” shall be Next Equity Financing Securities from and after such closing, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant and the
“Warrant Price” shall be the lower of the Warrant Price then in effect and the Next Equity Financing Price from and after such closing, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant;
provided, that upon such date, if any, if the Warrant Price is changed to the Next Equity Financing pursuant to this sentence, this Warrant shall be exercisable for such number of shares of such Class as shall equal (i) One Hundred Eighty
Thousand Dollars ($180,000.00), divided by (ii) the Next Equity Financing Price, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant. As used herein (i) “Next Equity Financing” means
the first sale or issuance by the Company on or after the Issue Date of this Warrant set forth above, in a single transaction or series of related transactions, of shares of its convertible preferred stock or other senior equity securities to one or
more investors for cash for financing purposes; (ii) “Next Equity Financing Securities” means the type, class and series of convertible preferred stock or other senior equity security sold or issued by the Company in the Next Equity
Financing; and (iii) “Next Equity Financing Price” means the lowest price per share for which Next Equity Financing Securities are sold or issued by the Company in the Next Equity Financing. 

  
 3 

 SECTION 2.    ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

 2.1    Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the
outstanding shares of the Class payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number
and kind of securities and property which Holder would have received bad Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Class by reclassification
or otherwise into a greater number of shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are combined or
consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 

2.2    Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding
shares of the Class are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be
exercisable for the number, class and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in
accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events. 

2.3    Conversion of Preferred Stock. If the Class is a class and series of the Company’s convertible
preferred stock, in the event that all outstanding shares of the Class are converted, automatically or by action of the holders thereof, into common stock pursuant to the provisions of the Company’s Certificate of Incorporation, including,
without limitation, in connection with the Company’s initial, underwritten public offering and sale of its common stock pursuant to an effective registration statement under the Act (the “IPO”), then from and after the date on
which all outstanding shares of the Class have been so converted, this Warrant shall be exercisable for such number of shares of common stock into which the Shares would have been converted had the Shares been outstanding on the date of such
convers ion, and the Warrant Price shall equal the Warrant Price in effect as of immediately prior to such conversion divided by the number of shares of common stock into which one Share would have been converted, all subject to further adjustment
thereafter from time to time in accordance with the provisions of this Warrant. 
 2.4    Adjustments for Diluting
Issuances. Without duplication of any adjustment otherwise provided for in this Section 2, the number of shares of common stock issuable upon conversion of the Shares shall be subject to anti-dilution adjustment from time to time in the
manner set forth in the Company’s Articles or Certificate of Incorporation as if the Shares were issued and outstanding on and as of the date of any such required adjustment. 

2.5    No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of
Shares to be issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by
multiplying the fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price. 

2.6    Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of
Shares, the Company, at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon which such adjustment is based. The
Company shall, upon written request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such
adjustment. 

  
 4 

 SECTION 3.     REPRESENTATIONS AND COVENANTS OF THE COMPANY.

 3.1    Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as
follows: 
 (a)    The initial Warrant Price referenced on the first page of this Warrant is not greater than the price
per share at which shares of the Class were last sold and issued prior to the Issue Date hereof in an arms-length transaction in which at least $500,000 of such shares were sold. 

(b)    All Shares which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon
conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein
or under applicable federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the Class, common stock and
other securities as will be sufficient to permit the exercise in full of this Warrant and the conversion of the Shares into common stock or such other securities. 

(c)    The Company’s capitalization table attached hereto as Schedule 1 is true and complete, in all material
respects, as of the Issue Date. 
 3.2    Notice of Certain Events. If the Company proposes at any time to: 

(a)    declare any dividend or distribution upon the outstanding shares of the Class or common stock, whether in
cash, property, stock, or other securities and whether or not a regular cash dividend; 
 (b)    offer for subscription
or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights);

 (c)    effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the
outstanding shares of the Class; 
 (d)    effect an Acquisition or to liquidate, dissolve or wind up; or 

(e)    effect an TPO; 

then, in connection with each such event, the Company shall give Holder: 

(1)    at least seven (7) Business Days prior written notice of the date on which a record will be taken for such
dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Class will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in
(a) and (b) above; 
 (2)    in the case of the matters referred to in (c) and (d) above at least seven
(7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to exchange their shares for the securities or other
property deliverable upon the occurrence of such event); and 
 (3)    with respect to the TPO, at least seven
(7) Business Days prior written notice of the date on which the Company proposes to fi le its registration statement in connection therewith. 

Reference is made to Section 1.6(c) whereby this Warrant will be deemed to be exercised pursuant to Section 1.2 hereof if the Company does not give
written notice to Holder of a Cash/Public Acquisition as required by the terms hereof. Company will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting
requirements. 

  
 5 

 SECTION 4.    REPRESENTATIONS, WARRANTIES OF THE HOLDER. 

The Holder represents and warrants to the Company as follows: 

4.1    Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by
Holder are being acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the
specific purpose of acquiring this Warrant or the Shares. 
 4.2    Disclosure of Information. Holder is aware of
the Company’s business affairs and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant
and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional
information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3    Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities
involves substantial risk. Holder bas experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying
securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business
relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 

4.4    Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D
promulgated under the Act. 
 4.5    The Act. Holder understands that this Warrant and the Shares issuable upon
exercise hereof have not been registered under the Act in reliance upon a specific exemption there from, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder
understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or un less exemption from such registration and
qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act. 

4.6    Market Stand-off Agreement. The Holder agrees that the Shares shall
be subject to the Market Standoff provisions in Section [                    ] of the Investor Rights Agreement or similar agreement. 

4.7    No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of
this Warrant. 
 SECTION 5.    MISCELLANEOUS. 

5.1    Term; Automatic Cashless Exercise Upon Expiration. 

(a)    Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at
any time and from time to time on or before 6:00 PM, Eastern time, on the Expiration Date and shall be void thereafter. 

(b)    Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market
value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall

  
 6 

 
automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been
exercised, and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder. 

5.2    Legends. Each certificate evidencing Shares (and each certificate evidencing the securities issued upon
conversion of any Shares, if any) shall be imprinted with a legend in substantially the following form: 
 THE SHARES EVIDENCED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO OXFORD
FINANCE LLC DATED JULY 31, 2018, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER,
SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 5.3    Compliance with Securities Laws on
Transfer. This Warrant and the Shares issued upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance
with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably
requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to an affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D
promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. 

5.4    Transfer Procedure. After receipt by Oxford of the executed Warrant, Oxford may transfer all or part of this
Warrant to one or more of Oxford’s affiliates (each an “Oxford Affiliate”), by execution of an Assignment substantially in the form of Appendix 2. Subject to the provisions of Article 5.3 and upon providing the Company with
written notice, Oxford, any such Oxford Affiliate and any subsequent Holder, may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the Shares issuable directly or indirectly, upon conversion of the Shares,
if any) to any other transferee, provided however, in connection with any such transfer, the Oxford Affiliate(s) or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and
taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable). Notwithstanding any contrary provision here in, at all times prior to the IPO,
Holder may not, without the Company’s prior written consent, transfer this Warrant or any portion hereof, or any Shares issued upon any exercise hereof, or any shares or other securities issued upon any conversion of any Shares issued upon any
exercise hereof, to any person or entity who directly competes with the Company, except in connection with an Acquisition of the Company by such a direct competitor. 

5.5    Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall
be deemed delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or
electronic mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished
to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company receives
notice of a change of address in connection with a transfer or otherwise: 

  
 7 

 Oxford Finance LLC 

133 N. Fairfax Street 

Alexandria, VA 22314 
 Attn:
Legal Department 
 Telephone: ([        ])
[        -        ] 
 Facsimile:
([        ]) [        -        ] 

Email:
[                                @         
           .        ] 
 Notice to the Company
shall be addressed as follows until Holder receives notice of a change in address: 
 ACUTUS MEDICAL, INC. 

2210 Faraday Avenue 
 Suite 100

 Carlsbad, CA 92008 
 Attn:
[                            ] 

Fax: ([        ])
[        -        ] 
 Email:
[                                @         
           .        ] 
 With a copy (which
shall not constitute notice) to: 
 Wilson Sonsini Goodrich & Rosati 

650 Page Mill Road 
 Palo Alto,
CA 94304 
 Attn:
[                            ] 

Email:
[                                @         
           .        ] 

5.6    Waiver. This Warrant and any term hereof may be changed, waived discharged or terminated (either generally
or in a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7    Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of
this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8    Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which
together shall constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any
amendment thereto. 
 5.9    Governing Law. This Warrant shall be governed by and construed in accordance with
the laws of the State of California, without giving effect to its principles regarding conflict of law. 

5.10    Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise
affect the meaning of any provision of this Warrant. 
 5.11    Business Days. “Business Day” is
any day that is not a Saturday Sunday or a day on which Oxford is closed. 
 [Remainder of page left blank intentionally] 

[Signature page follows] 

  
 8 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by
their duly authorized representatives effective as of the Issue Date written above. 
  

			
	“COMPANY”
	
	ACUTUS MEDICAL, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

	
	“HOLDER”
	
	OXFORD FINANCE LLC
		
	By:	 	  

		
	Name:	 	  

		 	(Print)
		
	Title:	 	  

  
 [Signature Page to
Warrant to Purchase Stock] 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by
their duly authorized representatives effective as of the Issue Date written above. 
  

			
	“COMPANY”
	
	ACUTUS MEDICAL, INC.
		
	By:	 	
                     
                    

		
	Name:	 	  

		
	Title:	 	  

	
	“HOLDER”
	
	OXFORD FINANCE LLC
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

  
 [Signature Page to
Warrant to Purchase Stock] 

 APPENDIX 1 

  
 Appendix 1 

 APPENDIX 2 

  
 Appendix 2 

 SCHEDULE 1EX-10.9

 Exhibit 10.9 

[***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively
harmful if publicly disclosed. 
 UNIVERSITY OF MINNESOTA 

EXCLUSIVE PATENT LICENSE AGREEMENT 

THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a
constitutional corporation under the laws of the state of Minnesota, having a place of business at 1000 Westgate Drive, Suite 160, St. Paul, Minnesota 55114 (the “University”), and the Licensee identified below. The University and the
Licensee agree that: 
 The Terms and Conditions of Exclusive Patent License Agreement attached hereto as Exhibit A (the “Terms and
Conditions”) are incorporated herein by reference in their entirety. In the event of a conflict between provisions of this Agreement and the Terms and Conditions, the provisions in this Agreement shall govern. Capitalized terms used in this
Agreement without definition shall have the meanings given to them in the Terms and Conditions. The section numbers used in the parentheses below correspond to the section numbers in the Terms and Conditions. 

1.    Licensee (§1.8): Acutus Medical, Inc., a corporation under the laws of Delaware. 

2.    Field(s) of Use (§1.3): All 

3.    Territory (§1.16): Any country or territory where issued and unexpired Licensed Patents and/or
Licensed Patent Applications exist. 
 4.    Effective Date (§2): Date of the last signature of the
Agreement. 
 5.    Licensed Technology: 

5.1.    Licensed Patents(s) (§1.4): 
  

							
	 Patent No.
	 	 Country
	    	 Issue Date
	    	 Title

	 7,841,986
	 	USA	    	11/30/10	    	Methods and apparatus of three dimensional cardiac electrophysiological imaging

  
 1 

 5.2.    Licensed Patent Applications (§1.5): 

 

							
	 Application

No.              
	  	 Country
	  	 Filing Date
	  	 Title

	 60/799,510
	  	USA	  	5/10/2006	  	Methods and apparatus of three dimensional cardiac electrophysiological imaging
				
	 WO2007134190
	  	PCT	  	5/10/2007	  	Methods and apparatus of three dimensional cardiac electrophysiological imaging
				
	 07783610.4
	  	Europe	  	5/10/2007	  	Methods and apparatus of three dimensional cardiac electrophysiological imaging
				
	 61/817,710
	  	USA	  	04/30/2013	  	Spectral-spatio-temporal imaging of cardiac electrical activity

 6.    Patent-Related Expenses (§§1.10 & 6.3): [Select one
of the following) 
  

	 	☐	 The Licensee has no obligation under this Agreement to reimburse the University for Patent-Related Expenses.

  

	 	☒	 The Licensee shall reimburse the University for Patent-Related Expenses incurred before and during the Term as
provided in section 6.3 of the attached Terms and Conditions. Patent-Related Expenses incurred as of the Effective Date are approximately $[***]. 

  

	 	☐	 The Licensee shall reimburse the University for Patent-Related Expenses incurred during the Term as provided in
section 6.3 of the Terms and Conditions. The Licensee shall have no obligation to reimburse the University for Patent-Related Expenses incurred before the Effective Date. 

 

	 	☐	 The Licensee shall reimburse the University for Patent-Related Expenses incurred before the Effective Date,
payable as follows:         . The Licensee shall have no obligation to reimburse the University for Patent-Related Expenses during the Term. 

  
 2 

 7.    Sublicense Rights (§3.1.2): [Select one of the
following] 
  

	 	☒	 Yes 

  

	 	☐	 No 

8.    Federal Government Rights (§3.2): [Select one of the following] 

 

	 	☒	 Yes 

  

	 	☐	 No 

9.    Performance Milestones (§5.1): The Licensee shall achieve the following milestones: 

 

			
	 Milestone
	    	 Milestone Date

	Initiation of in-vitro proof of concept study	    	12 months from Effective Date
		
	Completion of system design for clinical studies	    	24 months from Effective Date
		
	Completion of clinical development program for approval	    	36 months from Effective Date
		
	Submission to U.S. or European regulatory body for approval	    	48 months from Effective Date

 Licensee may extend a Performance Milestone for a mutually agreed upon time if a force majeure event occurs,
which time shall be reasonably sufficient to overcome such force majeure event and able to perform such milestone. A force majeure means an event beyond the reasonable control of a party, which by the exercise of due diligence, such party is unable
to overcome and which make such party’s performance impossible or as impracticable as reasonably to be considered impossible under the circumstances, including, without limitation, a change of regulatory pathway or other regulatory delays,
problems with clinical trial protocols or designs or adverse events. 
 Licensee may automatically extend one Performance Milestone by six
months (and all subsequent Performance Milestones), without the prior consent of the University, upon the payment of a five thousand dollar ($5,000) extension fee. Thereafter, Licensee may extend Performance Milestones by six months (and all
subsequent Performance Milestones), with the prior consent of the University, upon the payment of a five thousand dollar ($5,000) extension fee for each extension. 

  
 3 

 10.    Commercialization Reports (§5.4): On
January 1 of each calendar year, the Licensee shall deliver written commercialization reports to the University as provided in section 5.4 of the Terms and Conditions. 

11.    Payments (§6.1). All amounts are non-refundable, and
payable as defined below or as specified in the University’s invoice. 
 11.1.    Upfront Payment: [***] dollars
($[***]) payable within five (5) business days after the Effective Date. 
 11.2.    Annual Maintenance Fee: [***]
dollars ($[***]) payable beginning on the third anniversary of the Effective Date and on each anniversary of the Effective Date thereafter. 

11.4.    Running Royalties and Annual Minimums. 

11.4.1.    Subject to subsection 11.4.2, the Licensee shall pay the University a royalty of [***] percent
([***]%) of the Net Sales Amount of Commercial Sales of Licensed Products, determined and payable as provided in section 6.4 of the Terms and Conditions. 

If the Licensee, solely in order to make (including to have made on its behalf), use, offer to sell or sell (including to have sold on its
behalf), offer to lease or lease (including to have leased on its behalf), import, or otherwise offer to dispose or dispose of Licensed Products in the Field of Use in the Territory without infringing the valid and subsisting intellectual property
rights of a Third Party, has taken a royalty-bearing license from the Third Party, upon the Licensee’s written request to the University, the royalty due and owing under this subsection 11.4.1 of this Agreement shall be reduced for all
Commercial Sales of Licensed Products made after the thirtieth (30th) day after the University’s receipt of such request, by an amount equal to fifty percent (50%) of the amount of the running royalty payable to the Third Party in connection
with granting such license; provided, however, the amount of the royalty due and owing under subsection this 11.4.1 shall not be reduced under this subsection below [***] percent ([***]%) Upon the University’s written request, the Licensee
shall promptly deliver to the University a true, correct and complete copy of the executed license and all other related agreements with the Third Party. 

11.4.2.    The annual minimum amount of royalties owed by the Licensee under subsection 11.4.1 shall be as
follows for each of the years below. A year begins and ends on the anniversary of the Effective Date. By way of example, Year 5 means the year beginning on the fourth anniversary of the Effective Date and ending on the fifth anniversary of the
Effective Date. 

  
 4 

					
	 Year(s)
	  	Minimum Amount of Royalties Owed	 
	 5
	  	$	[***]	 
	 6 and 7
	  	$	[***] each year	 
	 7+
	  	$	[***] each year	 

 11.5.    Sublicense Fees. Within thirty (30) days after the last day of each calendar
quarter, during the term of this Agreement and the Post-termination Period, the Licensee shall pay to the University the following as earned by the Licensee during such quarter: 

11.5.1.    Sublicense Royalties. The Licensee shall pay the University [***] percent ([***]%) of the Net
Sales Amount of Commercial Sales of Licensed Products made by all Sublicensees subject to and in accordance with Section 11.4. 

11.5.2.    Sublicense Revenues. The Licensee shall pay the University [***] percent ([***]%) of all
Sublicense Revenues received during the first year of the Term, payable on the first anniversary of the Effective Date; and, thereafter, [***]% of all Sublicense Revenues, payable on each subsequent anniversary of the effective Date. 

11.6.    Other Payments: Financial Milestones payable upon achievement of the following milestones 

 

			
	 Milestone
	  	 Payment

	Approval received from U.S. regulatory agency	  	Thirty five thousand dollars ($35,000)
		
	First Commercial Sale outside the U.S.	  	One hundred thousand dollars ($100,000) due within 12 months from milestone
		
	First Commercial Sale in the U.S.	  	One hundred thousand dollars ($100,000) due within 6 months from milestone

 11.8.    Transfer Payment: [***] dollars ($[***]) payable as provided in section 12.5 of
the Terms and Conditions. 
 11.9.    Administrative Handling Fee: [***] dollars ($[***]) payable as provided in
subsection 8.1.1 of the Terms and Conditions. 
 11.10.    Interest Rate: [***] dollars ($[***]) per annum. 

11.11.    Other: None 

  
 5 

 12.    Licensee’s Address for Notice (§12.13).
Notices will be sent to the Licensee at: 
 Acutus Medical, Inc. 

Attn: Randy Werneth, President & CEO 

10840 Thornmint Road, Suite 100 

San Diego, CA 92127 
 Facsimile
No.: 
 Email:
[                                         
                   ] 

13.    Licensee’s Contact Person for Patent Prosecution Consultation (§4.2.1). The University will,
as set forth in this Agreement, communicate with the contact person named below with respect to patent prosecution and maintenance: (Upon ten (10) days prior written notice to the University, the Licensee may change the person designated
below.) 
 Acutus Medical, Inc. 

Attn: Randy Werneth, President & CEO 

10840 Thornmint Road, Suite 100 

San Diego, CA 92127 
 Facsimile
No.: 
 Email:
[                                         
                   ] 
 IN WITNESS
WHEREOF, the parties hereto have caused their duly authorized representatives to execute this Agreement 
  

									
	Regents of the University of Minnesota	 		 	Acutus Medical, Inc.
					
	By:	 	 /s/ Jay W. Schrankler
	 		 	By:	 	 /s/ Randy Werneth

		 	Jay W. Schrankler	 		 		 	Randy Werneth
		 	Executive Director	 		 		 	President & CEO
		 	Office for Technology Commercialization	 		 		 	
					
	Date:	 	4-10-14	 		 	Date:	 	April 21, 2014

  
 6 

 UNIVERSITY OF MINNESOTA 

EXHIBIT A 
 Terms and
Conditions 
 Exclusive Patent License Agreement 

These terms and conditions to the Exclusive Patent License Agreement (“Terms and Conditions”) govern the grant of license by Regents
of the University of Minnesota (“University”) to the Licensee identified in the Exclusive Patent License Agreement (the “EPLA”). These Terms and Conditions are incorporated by reference into the EPLA. All section references in
these Terms and Conditions refer to provisions in these Terms and Conditions unless explicitly stated otherwise. 

1.    Definitions. For purposes of interpreting this Agreement, the following terms have the following meanings: 

1.1.    “Affiliate” means with respect to the Licensee or a Sublicensee, an entity that controls the Licensee or
the Sublicensee, as the case may be, is controlled by the Licensee or Sublicensee, or along with the Licensee or Sublicensee, is under the common control of a Third Party. An entity shall be deemed to have control of the controlled entity if it
(i) owns, directly or indirectly, ten percent (10%) or more of the outstanding voting securities of the controlled entity, or (ii) has the right, power or authority, directly or indirectly, to direct or cause the direction of the policy
decisions of the controlled entity, whether by ownership of securities, by representation on the controlled entity’s governing body, by contract, or otherwise. 

1.2.    “Commercial Sale” means a bona fide sale, use, lease, transfer or other commercial disposition for a
value of a Licensed Product by the Licensee or a Sublicensee, or their respective Affiliates, to a Third Party that is not an Affiliate of the Licensee or a Sublicensee. Sales of Licensed Products as clinical samples or other transfers of Licensed
Products for use in research and development of such Licensed Products are exempt from royalty payments. 

1.3.    “Field of Use” means the field(s) of use described in section 2 of the EPLA. 

1.4.    “Licensed Patent” means (a) the patent(s) described in section 5.1 of the EPLA, (b) any issued
and unexpired patent(s) issued during the Term that arose out of a Licensed Patent Application, and (c) any registrations, renewals, extensions, reissues or reexaminations of (a) and (b), and (d) any foreign counterparts of the
foregoing. 
 1.5.    “Licensed Patent Application” means (a) the pending patent application(s) described
in section 5.2 of the EPLA, (b) any patent applications filed by the University claiming 

  
 A-1 

 
inventions disclosed in the patent application(s) described in (a), (c) any related applications including, continuations,
continuations-in-part, substitution, extension and divisionals of a Licensed Patent Application, (d) any patent application claiming priority to any patent
application in (a), (b), or (c), and (e) any foreign counterparts of the foregoing; but, as to (c) only to the extent that a claim in a continuation-in-part
application is described and enabled by the specification of a patent application listed in Section 5.2 of the EPLA. 

1.6.    “Licensed Product” means any product or good in the Field of Use that is made by, made for, sold,
transferred, or otherwise disposed of by the Licensee, its Sublicensees, or Affiliates of Licensee or its Sublicensees, during the Term and the Post-termination Period and that, but for the granting of the rights set forth in this Agreement, would
(i) infringe (including under the doctrine of equivalents, as applicable) one or more Valid Claims in a Licensed Patent; or (ii) is covered by one or more Valid Claims in a Licensed Patent Application. “Licensed Product” also
means any service provided by or for the Licensee or its Sublicensees, but for the granting of the rights set forth in this Agreement, would (i) infringe (including under the doctrine of equivalents, as applicable) one or more Valid Claims in a
Licensed Patent; or (ii) is covered by one or more Valid Claims in a Licensed Patent Application. For clarification, a Licensed Product does not include catheters unless such catheters contain technology that would infringe one or more Valid
Claims in a Licensed Patent or is covered by one or more Valid Claims in a Licensed Patent Application. 

1.7.    “Licensed Technology” means collectively each Licensed Patent and each Licensed Patent Application. 

1.8.    “Licensee” means the entity identified in section 1 of the EPLA. 

1.9.    “Net Sales Amount” means the gross amount received for a Commercial Sale of a Licensed Product minus
(i) all trade, quantity, and cash discounts and rebates actually allowed, (ii) all credits and allowances actually granted due to rejections, returns, billing errors, uncollected amounts, and retroactive price reductions,
(iii) applicable duties and tariffs, (iv) applicable excise, sale, use, and other taxes and compulsory payments to governmental authorities,; and (v) the cost of shipping, packing, installation, insurance, and other transportation of
the Licensed Products. 
 In the event that a Licensed Product is sold in combination with another product, component or service for which
no royalty would be due hereunder if sold separately, the Net Sales Amount from such combination sales for purposes of calculating the amount of royalties due under this Agreement shall be calculated by multiplying the Net Sales Amount of the
combination product by the fraction A/(A+B), where A is the average gross selling price during the previous calendar quarter of the Licensed Product sold separately and B is the gross selling price during the previous calendar quarter of the
combined product(s), component(s) and/or service(s). In the event that a substantial number of separate sales were not made during the previous calendar quarter, then the Net Sales Amount shall be reasonably allocated based upon 

  
 A-2 

 
the proportion of value of the Licensed Product and such other product component or service included in such combination sale. 

1.10.    “Patent-Related Expenses” means reasonable, documented, out-of-pocket costs and expenses (including out-of-pocket attorneys’ fees, patent agent fees and governmental filing fees)
that the University incurs in prosecuting and maintaining the Licensed Technology. 
 1.11.    “Performance
Milestone” means an act or event specified in section 5.1 and described in section 9 of the EPLA. 

1.12.    “Post-termination Period” means the one hundred eighty (180) day period commencing on the date of
termination or expiration of the Term. 
 1.14.    “Sublicense Revenues” means all revenue, in whatever form
but excluding Sublicense Royalties, actually received by the Licensee or any of its Affiliates from a Sublicensee in consideration of its granting a such Sublicensee a sublicense to any of its rights under this Agreement, including, without
limitation, annual milestone attainment, sublicense issuance, maintenance or up-front payments, or technology access fee. Sublicense Revenue shall exclude (a) royalties and profit sharing payments;
(b) amounts received for equity or debt securities of Licensee or its Affiliates or the sale of all or substantially all of the business or assets of Licensee or its Affiliates to which this Agreement pertains; (c) any amounts received as
reimbursement of research and/or product development, or patent prosecution, defense, enforcement and maintenance expenses, (d) amounts received for achievement of milestones based upon events substantially similar to the milestone events
identified under this Agreement; and (e) amounts received for the supply of Licensed Product by or on behalf of Licensee or its Affiliates to such Sublicensee. 

1.15.    “Sublicense Royalties” means a royalty paid to the Licensee or any of its Affiliates that is earned on
Commercial Sales of Licensed Products by Sublicensees and that is determined as percentage of the Net Sales Amount of such Commercial Sale or as a per unit amount by the Sublicensee. 

1.16.    “Sublicensee” means any non-Affiliated Third Party to whom
Licensee has granted the right to manufacture and sell Licensed Products. 
 1.17.    “Territory” means the
geographical area described in section 3 of the EPLA. 
 1.18.    “Third Party” means any party other than the
University or Licensee. 
 1.19.    “Transfer Payment” means the payment to be made by the Licensee to the
University specified in section 12.5 and described in section 11 of the EPLA. 

  
 A-3 

 1.20.    “Valid Claim” means a claim of (a) a Licensed
Patent Application that has not been pending for more than five (5) years from the application date, or (b) a Licensed Patent that has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of
competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 
 2.    Term. The term of this Agreement
commences on the Effective Date as defined in section 4 of the EPLA and, unless terminated earlier as provided In section 8, expires on the date on which both no Licensed Patent is active in the Territory and no Licensed Patent Application is
pending in the Territory (the “Term”). 
 3.    Grant of License. 

3.1.    The Licensee’s Rights. 

3.1.1.    Subject to the terms and conditions of this Agreement, the University hereby grants to the
Licensee, and the Licensee hereby accepts, an exclusive license under the Licensed Technology to make (including to have made on its behalf), use, offer to sell or sell (including to have sold on its behalf), offer to lease or lease (including to
have leased on its behalf), import, or otherwise offer to dispose or dispose of Licensed Products in the Field of Use in the Territory. No provision of this Agreement is to be construed to grant the Licensee, by implication, estoppel or otherwise,
any rights (other than the rights expressly granted it in this Agreement) to the Licensed Technology, a Licensed Patent or Licensed Patent Application, or to any other University-owned technology, patent applications, or patents. 

3.1.2.    The Licensee shall not sublicense its rights under this Agreement, unless otherwise provided in
section 7 of the EPLA. If so provided, the Licensee may sublicense it rights, through multiple tiers, under this Agreement only as follows: the Licensee shall deliver to the University a true and correct copy (with those terms not reasonably
necessary to determine compliance with this Agreement redacted) of the sublicense agreement or other agreement under which the Licensee purports or intends to grant such sublicense rights within ten (10) days after the execution of such
agreement. The Licensee shall not enter into such agreement if the terms of the agreement are inconsistent in any respect with the terms of this Agreement, including without limitation, sections 5.2 - 5.6, 6.5, 8.3, 9.5, 10.3, and 11.3. Any
sublicense made in violation of this subsection is void and constitutes an event of default under subsection 8.1.1. 

  
 A-4 

 3.1.3.    The Licensee may exercise the license granted
under this Section 3.1 through one or more of its Affiliates, provided that Licensee shall be responsible for its Affiliates’ compliance with this Agreement. 

3.2.    The United States Government’s Rights. If the University indicated in section 8 of the EPLA that the United
States federal government funded the development, in whole or in part, of the Licensed Technology, then, (i) the federal government may have certain rights in and to the Licensed Technology as those rights are described in Chapter 18, Title 35
of the United States Code and accompanying regulations, including Part 401, Chapter 37 of the Code of Federal Regulations, (ii) the parties’ rights and obligations with respect to the Licensed Technology, including the grant of license set
forth in subsection 3.1.1, are subject to the applicable terms of these laws and regulations. 
 3.3.    The
University’s Rights. The University retains an Irrevocable, world-wide, royalty-free, non-exclusive right to use the Licensed Technology for teaching, research and educational purposes; provided, however,
that such use does not involve the University producing or manufacturing products or providing services for sale. The University shall have the right to sublicense its rights under this section to one or more
non-profit academic or research institutions. For purposes of clarification “providing services” shall not include sponsored research wherein the University receives funding to cover the direct
and/or indirect costs of such research. 
 4.    Applications and Patents. 

4.1.    Pre-EPLA Patent Filings. The Licensee acknowledges that it has reviewed
each Licensed Patent and each Licensed Patent Application and that it will not dispute the inventorship, validity, or enforceability of any of the claims made in a Licensed Patent or a Licensed Patent Application, provided Licensee may file a
counterclaim disputing inventorship, validity or enforceability of any Licensed Patent or Licensed Patent Application in response to any actual suit by the University alleging patent infringement. The Licensee further represents that as of the
Effective Date, it has not and does not manufacture, have manufactured, offer to sell, sell, offer to lease, lease, or import (a) any product or good that infringes (including under the doctrine of equivalents, as applicable) a claim in any
Licensed Patent or Licensed Patent Application, or (b) any product or good that is made using a process or machine that infringes (including under the doctrine of equivalents, as applicable) a claim in a Licensed Patent or Licensed Patent
Application. 
 4.2.    Patent Application Filings during the Term of this Agreement. 

4.2.1.    The University, in consultation with the Licensee, shall determine in which countries patent
application(s) will be filed and prosecuted with respect to the Licensed Technology. The University shall retain counsel of its choice that is reasonably acceptable to Licensee to file, prosecute, and maintain such the Licensed Technology.

  
 A-5 

 
The University shall inform the Licensee of the status of the filing, prosecution, and maintenance of the Licensed Technology, including delivering to the Licensee pertinent notices, written and
oral communications with governmental offices and officials, and documents, including those submitted to such government offices and officials, and shall consult with the Licensee on the filing, prosecution, and maintenance of the Licensed
Technology, including providing Licensee a reasonable opportunity to review and comment on material submissions and correspondences with government offices and officials and incorporating Licensee’s reasonable comments and suggestions with
respect thereto. The Licensee shall cooperate with the University in the filing and prosecution of all patent applications with respect to the Licensed Technology. In furtherance of the foregoing, the Licensee shall notify the University, in
writing, of the individual whom the Licensee has designated to consult and cooperate as provided in this subsection and is identified in section 13 of the EPLA. The Contact Person shall respond to the University’s request for consultation and
cooperation on a pending matter within fifteen business days or sooner as may be required under the circumstances. If the Contact Person fails to respond in such time period, the University, exercising its own judgment and discretion, may respond to
the matter as it deems appropriate. Except as provided in subsection 4.2.2, the Licensee shall reimburse the University for all Patent-Related Expenses as provided infection 6.3 and in section 6 of the EPLA. 

4.2.2.    The grant of license in section 3.1 and the definition of Territory in section 1.16 shall not
extend to or include any country in which Licensee elects, In writing to the University, not to pay or reimburse the payment of the cost, in whole or in part, to seek or maintain intellectual property protection. 

4.2.3.    No provision of this Agreement limits, conditions, or otherwise affects the University’s
right to prosecute a patent application with respect to the Licensed Technology in any country, except as expressly set forth herein. The University retains the sole and exclusive right to file or otherwise prosecute a patent application with
respect to the Licensed Technology, except as set forth herein. The Licensee shall cooperate with the University in the filing and prosecution of all patent applications with respect to the Licensed Technology. In the event the University elects not
to file, prosecute or maintain any of the Licensed Technology, the University shall notify the Licensee at least sixty (60) days prior to the next applicable deadline for such Licensed Technology, in which case the Licensee shall have the right
(but not the obligation) to control the filing, prosecution and maintenance of such Licensed Technology (including any Licensed Patents arising therefrom), at its own expense with counsel of its own choice. Licensee shall provide University with
copies of filings and communications with respect to Patent Applications filed by Licensee under this Section 4.2.3. 

4.3.    Rights in the Licensed Patents and Licensed Patent Applications. No provision of this Agreement grants the
Licensee any rights, titles, or interests (except as expressly provided 

  
 A-6 

 
hereunder, including the grant of license in subsection 3.1.1) in the Licensed Patents or Licensed Patent Applications, notwithstanding the Licensee’s payment of all or any portion of the
patent prosecution, maintenance, and related costs. 
 5.    Commercialization. 

5.1.    Commercialization and Performance Milestones. The Licensee shall use its commercially reasonable efforts,
consistent with sound and reasonable business practices and judgment, to commercialize the Licensed Products as soon as practicable and to maximize sales thereof. The Licensee shall perform, or shall cause to happen or be performed, as the case may
be, all the Performance Milestones described in section 9 of the EPLA in accordance with the terms provided in section 9 of the EPLA. 

5.2.    Covenants Regarding the Manufacture of Licensed Products. The Licensee hereby covenants and agrees that
(i) the manufacture, use, sale, or transfer of Licensed Products shall comply with all applicable federal and state laws, including all federal export laws and regulations; and (ii) the Licensed Products shall not be defective in design or
manufacture. The Licensee hereby further covenants and agrees that, to the extent required pursuant to 35 United States Code Section 204, it shall, and it shall cause Licensee’s Affiliates, each Sublicensee, and its Sublicensee’s
Affiliates, to substantially manufacture in the United States of America all products embodying or produced through the use of an invention that is subject to the rights of the federal government of the United States of America, subject to any
waiver that may be available under applicable laws. At Licensee’s request, University shall reasonably assist Licensee, its Affiliates, its Sublicensees, and its Sublicensees’ Affiliates to request a waiver to the requirement under 35
United States Code Section 204. 
 5.3.    Export and Regulatory Compliance. The Licensee understands that the Arms
Export Control Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR,) and the Export: Administration Act (EAA), including its Export Administration Regulations (EAR), are some (but not all) of the laws and
regulations that comprise the U.S. export laws and regulations. Licensee further understands that the U.S. export laws and regulations include (but are not limited to): (i) ITAR and EAR product/service/data-specific requirements; (ii) ITAR and
EAR ultimate destination-specific requirements; (iii) ITAR and EAR end user-specific requirements; (iv) Foreign Corrupt Practices Act; and (v) anti-boycott laws and regulations. The Licensee shall comply with all then-current
applicable export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations) pertaining to the Licensed Products (including any associated products, items, articles, computer software, media, services, technical
data, and other information). The Licensee certifies that it shall not, directly or indirectly, export (including any deemed export), nor re-export (including any deemed export) the Licensed Products
(including any associated products, items, articles, computer software, media, services, technical data, and other information) in violation of U.S. export laws and regulations or other applicable U.S. laws and regulations. The Licensee shall
include an appropriate provision in its agreements with its authorized Sublicensees to assure that these parties comply with all then-current applicable U.S. export laws and regulations and other applicable U.S. laws and regulations. 

  
 A-7 

 5.4.    Commercialization Reports. Throughout the Term add during the
Post-termination Period, and within thirty (30) days of the date specified in the schedule set forth in section 10 of the EPLA, the Licensee shall deliver to the University written reports of the Licensee’s, Licensee’s
Affiliates’, Sublicensees’ and the Sublicensees’ Affiliates’ efforts and plans to commercialize the Licensed Technology and to manufacture, offer to sell, or sell Licensed Products. 

5.5.    Use of the University’s Name and Trademarks or the Names of University Faculty, Staff, or Students. No
provision of this Agreement grafts the Licensee, Licensee’s Affiliates, Sublicensee or Sublicensee’s Affiliates any right or license to use the name, logo, or any marks owned by or associated with the University or the names, or identities
of any member of the faculty, staff, or student body of the University. The Licensee shall not use and shall not permit a Sublicensee to use any such logos, rriarks, names, or identities without the University’s and, as the case may be, such
member’s prior written approval. Notwithstanding the foregoing, the Licensee, its Affiliates, Sublicensees, and Sublicensees’ Affiliates may, without University’s prior permission, reasonably utilize University’s name or names of
University employees in statements of fact (provided such statements do not imply endorsement of any product of the Licensee, its Affiliates, Sublicensees or Sublicensees’ Affiliates), in legal proceedings, regulatory filings and due diligence
investigations of Licensee. 
 5.6.    Governmental Markings. 

5.6.1.    The Licensee shall mark all Licensed Products, where feasible, with patent notice appropriate
under Title 35, United States Code. 
 5.6.2.    As between the parties, the Licensee is responsible for
obtaining all necessary governmental approvals for the development, production, distribution, sale, and use of any Licensed Product, at the Licensee’s expense, including, without limitation, any safety studies, The Licensee is responsible for
including with the Licensed Product any warning labels, packaging and instructions as to the use and the quality control for any Licensed Product. 

5.6.3.    The Licensee agrees to register this Agreement with any foreign governmental agency that requires
such registration, and the Licensee shall pay all costs and legal fees in connection with such registration. The Licensee shall comply with all foreign laws affecting this Agreement or the sale of Licensed Products. 

6.    Payments, Reimbursements, Reports, and Records. 

  
 A-8 

 6.1.    Payments. The Licensee shall pay all amounts due under this
Agreement by check (payable to the “Regents of the University of Minnesota” and sent to the address specified in section 12.13), wire transfer, or any other mutually agreed-upon method of payment. 

6.2.    Interest. All amounts due under this Agreement shall bear interest as provided in section 11 of the EPLA on the
entire unpaid balance computed from the due date until the amount is paid. 
 6.3.    Reimbursement of Patent-Related
Expenses. The Licensee shall pay invoices for Patent-Related Expenses incurred during the Term of this Agreement within thirty (30) days of its receipt of the University’s invoice. With respect to each invoice, the University shall use
reasonable efforts to specify the date on which the Patent-Related Expense was incurred and the purpose of the expense (including, as applicable, a summary of patent attorney services giving rise to the expense) and provide receipts and other
reasonable documentation supporting the incurrence of Patent-Related Expenses; provided, however, without limiting the University’s obligations under section 4.2, the University is not required to disclose to the Licensee any information that
is protected by the University’s attorney-client privilege. Patent- Related Expenses incurred as of the Effective Date are set forth in section 6 of the EPLA. Licensee shall pay one-third of such
Patent-Related Expenses incurred as of the Effective Date on each of the following: (i) the Effective Date of the Agreement, (ii) the first anniversary or the Effective Date, and (iii) the second anniversary of the Effective Date. The
University reserves the right to require that Licensee provide and maintain a reasonable advance deposit with the University to ensure payment of Patent-Related expenses, provided that such deposit shall be refundable upon termination or expiration
of this Agreement if there are no outstanding Patent-Related Expenses. If there is a dispute regarding an invoice under this Section 6.3, the parties will attempt to resolve such dispute in an amicable manner prior to initiating termination for
breach under Article 8. 
 6.4.    Royalty Payments/Sales Reports. Within sixty (60) days after the last day of the
second and fourth calendar quarters during the Term and the Post-termination Period, the Licensee shall deliver to the University a written sales report in the form reasonably acceptable to the University, recounting the number and Net Sales Amount
(expressed in U. S. dollars) of all sales, leases, or other commercial dispositions of Licensed Products, whether made by the Licensee, its Affiliates, Sublicensees or Sublicensees’ Affiliates, during such semi-annual period. The Licensee shall
deliver such written report to the University even if the Licensee is not required hereunder to pay to the University a payment for sales, leases, or other commercial dispositions of Licensed Products during the semi-annual period. The Licensee
shall deliver along with such sales reports its payment for royalties owed on all Commercial Sales of Licensed Products by the Licensee, its Affiliates, Sublicensees and the Sublicensees’ Affiliates during such semi-annual period. 

6.5.    Records Retention and Audit Rights. 

  
 A-9 

 6.5.1.    Throughout the Term and the Post-termination
Period and for five (5) years thereafter, the Licensee, at its expense, shall keep and maintain and shall use commercially reasonable efforts to cause its Affiliates, each Sublicensee and such Sublicensee’s Affiliates and each non-affiliated Third Party that manufactures, sells, leases, or otherwise commercially disposes of Licensed products on behalf of the Licensee to keep and maintain complete and accurate records of all sales, leases,
and other commercial dispositions of Licensed Products during the Term and the Post-termination Period and all other records that are reasonably necessary for the determination of compliance with this Agreement. 

6.5.2.    In connection with an audit, the Licensee, upon written request, shall deliver, at
University’s expense, to the University and its representatives true, correct and complete copies of all documents and materials (including electronic records) reasonably necessary to determine compliance with this Agreement, including, without
limitation, all sublicenses granted (redacted as provided in section 3.1.2). 
 6.5.3.    To determine
the Licensee’s compliance with the terms of this Agreement, no more than once per calendar year and upon 10 business days advance written notice to Licensee, the University, at its expense (except as set forth in this subsection), may inspect
and audit the Licensee’s records referred to in subsection 6.5.1 at the Licensee’s address as set forth in this Agreement or such other location(s) as the parties mutually agree during the Licensee’s normal business hours. The
Licensee shall cooperate in the audit, including providing at no cost, commodious space in the Licensee’s place of business for the auditor, as reasonably available. The Licensee shall reimburse the University for all its out-of-pocket expenses to inspect and audit such records if the University, in accordance with the results of such inspection and audit, determines that the Licensee has
underpaid amounts owed to the University by at least three percent (3%) or twenty-five thousand dollars ($25,000), whichever is smaller, in a reporting period. The Licensee shall use commercially reasonable efforts to cause its Affiliates, each
Sublicensee and such Sublicensee’s Affiliates and each non-Affiliated Third Party that manufactures, sells, leases, or otherwise commercially disposes of Licensed Products on behalf of the Licensee to
grant the University a right to inspect and audit its Affiliates’, the Sublicensee’s, such Sublicensee’s Affiliates’ or such Third Party’s records substantially similar to the rights granted the University in this
subsection, provided that in any case, Licensee shall obtain for itself customary audit rights and, at the request of University, Licensee shall exercise such audit right with respect to Licensee’s Affiliates, Sublicensees, Sublicensees’
Affiliates or such Third Party and provide the results of such audit for inspection by University. In connection with, and before the commencement of, an audit, if the Licensee requests in writing to the University, then prior to conducting such
audit, the Licensee, the University and the auditor must enter into an agreement prohibiting the auditor and the University from disclosing the Licensee’s nonpublic, proprietary information to any Third Party without the

  
 A-10 

 
Licensee’s prior written consent; provided, however, that consistent with generally accepted auditing standards and the auditor’s professional judgment, the auditor may disclose such
information to the University and its agents, counsel, or consultants. The Licensee acknowledges that such an agreement is adequate to protect its legitimate interests, and the parties agree that there shall be no additional nondisclosure agreement
demanded as a condition to the commencement of an audit and the University’s exercising its rights under this subsection. 

6.6.    Currency and Checks. All computations and payments made under this Agreement shall be in United States dollars. To
determine the dollar value of transactions conducted in non-United States dollar currencies, the parties shall use the exchange rate for the currency into dollars as reported in the Wo// Street Journal as the
New York foreign exchange mid-range rate on the last business day of the month in which the transaction occurred. 

7.    Infringement. 

7.1.    If a party learns of substantial, credible evidence that a Third Party is making, using, or selling a product in
the Field of Use in the Territory that infringes a Licensed Patent, such party shall promptly notify the other party in writing of the possible infringement and in such notice describe in detail the information suggesting infringement of the
Licensed Patent. Prior to commencing any action to enforce a Licensed Patent, the parties shall enter into good faith negotiations on the desirability of bringing suit, the parties to the action, the selection of counsel, and such other matters as
the parties may agree to discuss. Following good faith negotiations on the desirability of bringing suit, the Licensee shall have the initial right, but not the obligation, to institute, prosecute and control any action, suit or proceeding to
enforce such Licensed Patent with respect to such infringement, or any declaratory judgment action with respect thereto (each, an “Enforcement Action”) at its expense, using legal counsel of its choice. In the event the Licensee fails to
initiate or defend any Enforcement Action with respect to any commercially significant infringement of any Licensed Patent within one hundred eighty (180) days of a request by the University to do so, the University shall have the right, but
not the obligation, to initiate such an Enforcement Action, at its expense, using legal counsel of its choice; provided that University shall consider in good faith Licensee’s rationale for not initiating an Enforcement Action (including
without limitation, any substantive concern regarding counterclaims by such infringing Third Party). University may be named by Licensee as a co-plaintiff in a suit initiated by Licensee only if:
(a) Licensee’s and University’s respective counsel recommend that such action is necessary in their reasonable opinion to achieve standing or a court has required or will require such joinder to pursue the action, (b) University
is not the first named party in the action, (c) the pleadings and any public statements by Licensee about the action state that Licensee is pursuing the action and that Licensee has the right to join University as a party, (d) Licensee
does not name University as a defendant in the suit; and (e) Licensee reimburses University for any costs or expenses University incurs in participating in the suit. No provision of this Agreement limits, conditions, or otherwise affects a
party’s statutory and common-law rights to commence an action 

  
 A-11 

 
to enforce a Licensed Patent except as expressly set forth herein. In any such action, the party controlling such action shall keep the other party reasonably informed of the status of such
action, and the other party agrees to cooperate with the controlling party and such other party will use reasonable efforts to permit access to relevant personnel, records, papers, information, samples and specimens during regular business hours,
each at the controlling party’s request and expense. As between the parties hereunder, any amounts recovered (less amounts actually paid for reasonable attorney’s fees and legal expenses) by the controlling party in any such action or
settlement that constitute compensation for lost profits or sales will be retained or paid over to Licensee, provided that such amount shall be considered as Net Sales Amounts subject to the royalty rate in subsection 11.4.1 of the EPLA. All other
amounts recovered (less amounts actually paid for reasonable attorney’s fees and legal expenses) by the controlling party in such action or settlement shall be retained by or paid over to Licensee, provided that such amount shall be considered
subject to the rate for Sublicense Revenues in subsection 11.5.2 of the EPLA. 
 7.2.    If any suit, action or
proceeding is brought or commenced Against the Licensee alleging the infringement of a patent or other intellectual property right owned by a Third Party by reason of the manufacture, use or sale of Licensed Products (each, a “Third Party
Infringement Claim”), the Licensee shall give the University prompt notice thereof. Licensee shall have the right to defend any such Third Party Infringement Claim, provided that if the validity of a Licensed Patent is questioned in such suit,
action or proceeding, the Licensee shall have no right to make any settlement or compromise which affects the scope, validity, enforceability or otherwise the Licensed Patent without the University’s prior written approval. The University will
reasonably assist Licensee and cooperate in defense of any Third Party Infringement Claim at the Licensee’s request and expense. If the Licensee is required to pay a royalty or other amount to a Third Party to make, have made, use, offer to
sell, sell, have sold, offer to lease, lease, import, or otherwise offer to dispose or dispose a Licensed Product as a result of a final judgment, or settlement of such Third Party Infringement Claim, then the Licensee shall be entitled to a royalty
stacking set forth in section 11.4.1 of the EPLA for such royalty or other amount. 

  
 A-12 

 8.    Termination. 

8.1.    By the University. 

8.1.1.    If the Licensee materially breaches or fails to perform one or more of its material obligations
under this Agreement, the University may deliver a written notice of default to the Licensee. Without further action by a party, this Agreement shall terminate if (a) the University has not been paid the full amount of the Administrative
Handling Fee set forth in section 11 of the EPLA, and (b) the default has not been cured in full within either sixty (60) days after the delivery to the Licensee of the notice of default if the default relates to a payment or reimbursement
obligation under this Agreement, or ninety (90) days after the delivery to the Licensee of the notice of default if the default relates to any other matter provided that, in each case, if Licensee disputes such default in good faith by
providing written notice to University during the applicable cure period, University and Licensee shall attempt to resolve the matter in an amicable fashion prior to initiating termination proceedings under Article 8. 

8.1.2.    The University may terminate this Agreement by delivering to the Licensee a written notice of
termination at least ten (10) days before the date of termination if the Licensee (i) becomes insolvent; (ii) voluntarily files or has filed against it a petition under applicable bankruptcy or insolvency laws that the Licensee fails
to have released within thirty (30) days after fifing; (iii) proposes any dissolution, composition, or financial reorganization with creditors or if a receiver, trustee, custodian, or similar agent is appointed; or (iv) makes a
general assignment for the benefit of creditors. 
 8.1.3.    The University may terminate this Agreement
immediately by delivering to the Licensee a written notice of termination if the Licensee or its agents or representatives commences or maintains an action in any court of competent jurisdiction or a proceeding before any governmental agency
asserting or alleging, in any respect, the invalidity or unenforceability of any of the Licensed Technology. The Licensee shall notify the University, in writing, at least thirty (30) days prior to the commencement of any such action or the
institution of any such proceeding. For clarity, this section 8.1.3 shall not apply to a counter claim filed by Licensee asserting or alleging, in any respect, the invalidity or unenforceability of any Licensed Technology in response to an actual
suit by the University. 
 8.2.    By the Licensee 

8.2.1.    Cause. If the University materially breaches or fails to perform one or more of its material
duties under this Agreement, the Licensee may deliver to the 

  
 A-13 

 
University a written notice of default. The Licensee may terminate this Agreement by delivering to the University a written notice of termination if the default has not cured in full within
ninety (90) days of the delivery to the University of the notice of default. 

8.2.1    Convenience. Licensee may terminate this Agreement for a reason other than for breach by
(i) providing ninety (90) days advance written notice of its decision to terminate; (ii) paying all amounts owing under the Agreement as of the effective date of termination; and (iii) paying the annual minimum payment of the
EPLA for the year following termination. If the termination occurs before the fifth anniversary of the Effective Date, the amount due under 8.2.1 (iii) is $15,000. 

8.2.1    
Patent-by-Patent. Licensee may terminate this Agreement as to any particular patent application or patent within the Licensed Technology by (i) giving
University written notice at least 30 days in advance of the effective date of termination selected by Licensee; (ii) paying all Patent Related Expenses associated with that particular patent application or patent through the effective date of
termination; (iii) paying all royalties due for Licensed Products with respect to the particular patent application or patent through the effective date of termination. From and after the effective date of a termination under this subsection
8.2.1 with respect to a particular patent application or patent, such patent application or patent in the particular country shall cease to be within the Licensed Technology for purposes of this Agreement. 

8.3.    Effect of Termination/Expiration. 

8.3.1.    In the event this Agreement is terminated for any reason, any sublicense granted under section
3.1.2 shall survive and be assigned to the University, provided such Sublicensee notifies University in writing within thirty days of the termination of this agreement that it agrees to be bound by the terms and conditions of this Agreement to the
extent applicable to the scope of such sublicense. Such Sublicensee’s financial obligations to University shall be limited to those due from the Licensee for the practice of such sublicense by such Sublicensee if this Agreement had remained in
effect. 
 8.3.2.    Post-termination Period. If the Licensee or University terminates this
Agreement under section 8.1 or 8.2, the Licensee may continue to offer to sell and sell, offer to lease and lease, and otherwise offer to dispose of or dispose of Licensed Products in the Territory that were manufactured before such termination. The
Commercial Sales of Licensed Products during the Post-termination Period shall be governed by the terms of this Agreement, including the obligation to pay royalties on such Commercial Sales as provided in this Agreement. 

9.    Release, Indemnification, and Insurance. 

9.1.    The Licensee’s Release. For itself and its employees, the Licensee hereby releases the University and its
regents, employees, and agents forever from any and all suits, 

  
 A-14 

 
actions, claims, liabilities, demands, damages, losses, or expenses (including reasonable attorneys’ and investigative expenses) relating to or arising out of the manufacture, use, lease,
sale, or other disposition of a Licensed Product, except to the extent arising from (i) any breach by University of this Agreement or (ii) the negligence or willful misconduct of University or any of its officers, employees and agents.

 9.2.    Indemnification. 

9.2.1.    The Licensee’s Indemnification. Throughput the Term and thereafter, the Licensee
shall indemnify, defend, and hold the University and its regents, employees, and agents harmless from all liabilities, damages, losses, or expenses (including reasonable attorneys’ and investigative expenses) (collectively, “Losses”)
resulting from any suits, actions, claims, or demands brought by any Third Party ^‘Claims”) relating to or arising out of the Licensee’s exercises or attempt to exercise any of the rights or licenses granted it under this
Agreement, including without limitation, the manufacture, use, lease, sale, or other disposition of a Licensed Product or the Licensee’s breach of any term of this Agreement; except to the extent such Losses arise from (i) any breach by
the University of this Agreement or (ii) the negligence or willful misconduct of such indemnified entity. 

9.2.2.    The University’s Indemnification. Subject to the limitations on liability set forth
in section 11, throughout the Term and thereafter, the University shall indemnify, defend, and hold the Licensee and its directors, employees, and agents harmless from all Losses resulting from any Claims relating to or arising out of the
University’s breach of this Agreement, negligence or willful misconduct. 

9.2.3.    Indemnification Procedure. To be eligible to be indemnified hereunder, the indemnified
entity shall provided the indemnifying party prompt notice of the Claim giving rise to the indemnification obligation under section 9.2.1 or 9.2.2, as the case may be, and the exclusive ability to defend (with the reasonable cooperation of the
indemnified entity) or settle any such Claim; provided, however, that the indemnifying party shall not enter into any settlement that admits fault, wrongdoing or damages (other than monetary damages) without the indemnified entity’s written
consent, such consent not to be unreasonably withheld or delayed. The indemnified entity shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any Claim that has been assumed by the indemnifying
party; provided that the indemnifying party shall have no obligation with respect to any Losses resulting from the indemnified entity’s admission, settlement or other communication without the prior written consent of the indemnifying party.

 9.3.    The Licensee’s Insurance. 

9.3.1.    Throughout the Term, or during such other period as the parties agree in writing, the Licensee
shall maintain, and shall cause each Sublicensee to maintain, in full force and effect comprehensive general liability (“CGL”) insurance, with single claim 

  
 A-15 

 
limits of at least one million U.S. dollars ($1,000,000). Such insurance policy shall include coverage for claims that may be asserted by the University against the Licensee under section 9.2 and
for claims by a Third Party against the Licensee or the University arising out of the purchase or use of a Licensed Product, with such product liability or clinical trial insurance coverage to be provided prior to the first commercial sale or use in
a clinical trial of a Licensed Product. Such insurance policy must name the University as an additional insured if the University so requests in writing. Upon receipt of the University’s written request, the Licensee shall deliver to the
University a copy of the certificate of insurance for such policy. 
 9.3.2.    The provisions of
subsection 9.3.1 do not apply if the University agrees in writing to accept the Licensee’s or a Sublicensee’s, as the case may be, self-insurance plan as adequate insurance. 

9.4.    Sublicensees - Release. The Licensee shall cause each Sublicensee to grant the University a release from
liabilities substantially similar to the release granted in favor of the University in section 9.1. 
 10.    Warranties. 

10.1.    Authority. Each party represents and warrants to the other party that it has full corporate power and authority to
execute, deliver, and perform this Agreement, and that no other corporate proceedings by such party are necessary to authorize the party’s execution or delivery of this Agreement. The University further represents and warrants (i) it has
the right to grant the rights and licenses granted herein; and (ii) it has not previously granted, and will not grant during the term of this Agreement, any right, license or interest in or to the Licensed Technology, or any portion thereof,
inconsistent with the rights granted to the Licensee herein. 
 10.2.    Disclaimers. 

10.2.1.    EXCEPT FOR THE EXPRESS WARRANTY SET FORTH ABOVE IN SECTION 10.1, EACH PARTY DISCLAIMS
AND EXCLUDES ALL WARRANTIES, EXPRESS AND IMPLIED, CONCERNING ANY SUBJECT MATTER OF THIS AGREEMENT, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF NON-INFRINGEMENT, OF MERCHANTABILITY AND OF FITNESS FOR A
PARTICULAR PURPOSE. 

  
 A-16 

 10.2.2.    The University expressly disclaims any
warranties concerning and makes no representations: 
  

	 	(i)	 that the Licensed Patent Applications will allowed or granted or that a patent will issue from any Licensed
Patent Application; 

  

	 	(ii)	 concerning the validity, enforceability, interpretation of claims or scope of any Licensed Patent; or

  

	 	(iii)	 that the exercise of the rights or licenses granted to the Licensee under this Agreement will not infringe a
Third Party’s patent or violate its intellectual property rights. 

 10.3.    Sublicensees -
Warranties. The Licensee shall cause each Sublicensee to give the University warranties and disclaimers and exclusions of warranties substantially similar to the warranty and disclaimers and exclusions of warranties in favor of the University in
section 10.1 and subsections 10.2.1 and 10.2.2. 
 11.    Damages. 

11.1.    Remedy Limitation. EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, NEITHER PARTY SHALL BE LIABLE FOR
LOST PROFITS, LOST BUSINESS OPPORTUNITY, INVENTORY LOSS, WORK STOPPAGE, LOST DATA OR ANY OTHER INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, OF ANY KIND. 

11.2.    Damage Cap. THE UNIVERSITY’S TOTAL LIABILITY FOR THE BREACH OR NONPERFORMANCE OF THIS AGREEMENT
SHALL NOT EXCEED THE TOTAL AMOUNT OF PAYMENTS PAID TO THE UNIVERSITY (LESS ANY AMOUNTS DISTRIBUTED TO INDIVIDUAL INVENTORS AND AMOUNTS RECEIVED AS PATENT RELATED EXPENSES) UNDER THIS AGREEMENT PRECEDING THE COMMENCEMENT OF ANY SUIT OR ACTION. THIS
LIMITATION APPLIES TO CONTRACT, TORT, AND ANY OTHER CLAIM OF WHATEVER NATURE. 
 11.3.    Sublicensees - Damages.
The Licensee shall cause each Sublicensee to agree to limitations of remedies and damages substantially similar to the limitations of remedies and damages set forth in sections 11.1 and 11.2. 

12.    General Terms 

12.1.    Access to University Information. 

12.1.1.    Data Practices Act. The parties acknowledge that the University is subject to the terms and
provisions of the Minnesota Government Data Practices Act, Minnesota Statutes §13.01 et seq. (the “Act”), and that the Act requires, with certain exceptions, the University to permit the public to inspect and copy any information that
the University collects, creates, receives, maintains, or disseminates. 

  
 A-17 

 12.1.2.    Confidentiality. To the extent permitted by
law, including as provided in the Act, the University shall hold in confidence the reports described in sections 5.4 and 6.4 and the records inspected in accordance with section 6.5 of the Terms and Conditions, and any other information that is
disclosed by Licensee to University under this Agreement which is designated as “Confidential” or proprietary” (collectively, “Confidential Information”) and may only disclose such Confidential Information to University
employees, agents and contractors who need to know such Information for the purpose of exercising the University’s rights or performing the University’s obligations under this Agreement and who are bound by written obligations of
confidentiality no less restrictive than those provided herein. Upon termination or expiration of this Agreement, the University shall return to Licensee all copies and embodiments of the Confidential Information, except that University may retain
one copy of the Confidential Information solely to determine its compliance with the confidentiality obligations herein. No provision of this Agreement is to be construed to further prohibit, limit, or condition the University’s right to use
and disclose any information in connection with enforcing this Agreement, in court or elsewhere, except as expressly provided herein. 

12.2.    Amendment and Waiver. The Agreement may be amended from time to time only by a written instrument signed by the
parties. No term or provision of this Agreement may be waived and no breach excused unless such waiver or consent is in writing and signed by the party claimed to have waived or consented. No waiver of a breach is to be deemed a waiver of a
different or subsequent breach. 
 12.3.    Applicable Law and Forum Selection. The internal laws of the state of
Minnesota, without giving effect to its conflict of laws principles, govern the validity, construction, and enforceability of this Agreement. A suit, claim, or other action to enforce the terms of this Agreement may be brought only in the state
courts of Hennepin County, Minnesota. The Licensee hereby submits to the jurisdiction of that court and waives any objections it may have to that court asserting jurisdiction over the Licensee or its assets and property. Notwithstanding the
foregoing, any dispute regarding the validity of any Licensed Patent shall be litigated in the U.S. District Court of Minnesota, and the parties agree not to challenge personal jurisdiction in such forum. 

12.4.    Assignment and Sublicense. Except as permitted under subsection 3.1.2 and section 12.5 of the Terms and
Conditions, the Licensee shall not assign or sublicense its interest or delegate its duties under this Agreement. Any assignment, sublicense, or delegation attempted to be made in violation of this section is void. Absent the consent of all the
parties, an assignment or delegation will not release the assigning or delegating party from its obligations accrued prior to the effective date of assignment. The Agreement inures to the benefit of the Licensee and the University and their
respective successors and permitted assigns, sublicensees and trustees. 

  
 A-18 

 12.5.    Change of Control. Notwithstanding section 12.4, the Licensee,
without the prior approval of the University, may assign all, but no less than all, its rights and delegate all its duties under this Agreement to another if (i) the Licensee delivers to the University written notice of the proposed assignment
(along with pertinent information about the terms of the assignment and assignee) at least five (5) days before the effective date of the event described in part iii of this paragraph, (ii) pay to the University the Transfer Payment prior
to the effective date of the event described in part iii of this paragraph, and (iii) the assignment is made as a part of and in connection with (a) the sale by the Licensee of all or substantially all of its assets to a successor in
interest, (b) the sale, transfer, or exchange by the shareholders, partners, or equity owners of the Licensee of a majority interest in the Licensee to a successor in interest, or (c) the merger of the Licensee into another corporation or
other business entity. Any assignment attempted to be made or made in violation of this subsection is void. 

12.6.    Collection Costs and Attorneys^ Fees. If a party fails to perform an obligation or otherwise breaches one or
more of the terms of this Agreement, the other party may recover from the non-performing breaching party all its reasonable costs (including actual attorneys’ and investigative fees) to enforce the terms
of this Agreement. 
 12.7.    Consent and Approves. Except as otherwise expressly provided, in order to be effective,
all consents or approvals required under this Agreement must be in writing. 
 12.8.    Construction. The headings
preceding and labeling the sections of this Agreement are for the purpose of identification only and are not to be employed or used for the purpose of construction or interpretation of any portion of the EPLA. As used herein and where necessary, the
singular includes the plural and vice versa, and masculine, feminine, and neuter expressions are interchangeable. 

12.9.    Enforceability. If a court of competent jurisdiction adjudges a provision of this Agreement to be unenforceable,
invalid, or void, such determination is not to be construed as impairing the enforceability of any of the remaining provisions hereof and such provisions will remain in full force and effect. 

12.10.    Entire Agreement. The parties intend this Agreement (including all attachments, exhibits, and amendments hereto)
to be the final and binding expression of their contract and agreement with respect to the subject matter hereof and the complete and exclusive statement of the terms thereof. The Agreement cancels, supersedes, and revokes all prior negotiations,
representations and agreements among the parties, whether oral or written, relating to the subject matter of this Agreement. 

12.11.    Language and Currency. Unless otherwise expressly provided in this Agreement and in order to be effective, all
notices, reports, and other documents and instruments that a party elects or is required to deliver to the other party must be in English, and all notices, 

  
 A-19 

 reports, and other documents and instruments detailing revenues and earned under this Agreement or expenses
chargeable to a party must be United States dollar denominated. 
 12.12.    No Third-Party Beneficiaries. No provision
of this Agreement, express or implied, is intended to confer upon any person other than the parties to this Agreement any rights, remedies, obligations, or liabilities hereunder. No Sublicensee may enforce or seek damages under this Agreement. 

12.13.    Notices. In order to be effective, all notices, requests, and other communications that a party is required or
elects to deliver must be in writing and must be delivered personally, or by facsimile or electronic mail (provided such delivery is confirmed), or by a recognized overnight courier service or by United States mail, first-class, certified or
registered, postage prepaid, return receipt requested, to the other party at its address set forth below or to such other address as such party may designate by notice given under this section: 

 

			
	If to the University:	  	 University of Minnesota
 Office for Technology
Commercialization
 200 Oak Street SE, Suite 280
 Minneapolis,
MN 55455
 Fax:
[                                        ]

E-mail:
[                                        
]

		
	 For notices sent
 under section 8,

with a copy to:
	  	 University of Minnesota
 Office of the General
Counsel
 Attn: Transactional Law Services
 360 McNamara Alumni
Center
 200 Oak Street S.E.
 Minneapolis, MN 55455-2006

Facsimile No.:
[                                        
]

		
	If to the Licensee:	  	As indicated in section 12 of the EPLA.

 12.14.    Relationship of Parties. In entering into, and performing their duties under
this Agreement, the parties are acting as independent contractors and independent employers. No provision of this Agreement creates or is to be construed as creating a partnership, joint venture, or agency relationship between the parties. No party
has the authority to act for or bind the other party in any respect. 
 12.15.    Security Interest. In no event may the
Licensee grant, or permit any person to assert or perfect, a security interest in the Licensee’s rights under this Agreement. 

12.16.    Survival. Immediately upon the termination or expiration of this Agreement, except for certain rights granted
for the Post-termination Period, all the Licensee’s rights under 

  
 A-20 

 
this Agreement terminate; provided, however, the Licensee’s rights and obligations that have accrued before the effective date of termination or expiration (e.g., the obligation to report
and make payments on sales, leases, or commercial dispositions of Licensed Products and to reimburse the University for Patent-Related Expenses) and the obligations specified in section 6.5.1 shall survive. The obligations and rights set forth in
sections 6.4 and 8.3 and sections 9,10, 11, and 12 also survive the termination or expiration of this Agreement. 

  
 A-21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]